Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics
RXRX Price/Volume Stats
| Current price | $7.65 | 52-week high | $16.75 |
| Prev. close | $7.77 | 52-week low | $4.54 |
| Day low | $7.63 | Volume | 2,065,800 |
| Day high | $8.04 | Avg. volume | 3,271,604 |
| 50-day MA | $9.85 | Dividend yield | N/A |
| 200-day MA | $8.28 | Market Cap | 1.65B |
RXRX Stock Price Chart Interactive Chart >
RXRX POWR Grades
- Growth is the dimension where RXRX ranks best; there it ranks ahead of 23.11% of US stocks.
- RXRX's strongest trending metric is Stability; it's been moving down over the last 177 days.
- RXRX ranks lowest in Quality; there it ranks in the 2nd percentile.
RXRX Stock Summary
- RECURSION PHARMACEUTICALS INC's stock had its IPO on April 16, 2021, making it an older stock than only 7.25% of US equities in our set.
- With a price/sales ratio of 34.16, RECURSION PHARMACEUTICALS INC has a higher such ratio than 96.01% of stocks in our set.
- As for revenue growth, note that RXRX's revenue has grown 176.57% over the past 12 months; that beats the revenue growth of 96.56% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to RECURSION PHARMACEUTICALS INC are SLDP, DTIL, EFTR, SRPT, and ALGS.
- RXRX's SEC filings can be seen here. And to visit RECURSION PHARMACEUTICALS INC's official web site, go to www.recursion.com.
RXRX Valuation Summary
- RXRX's price/earnings ratio is -6.6; this is 124.72% lower than that of the median Healthcare stock.
- Over the past 30 months, RXRX's price/sales ratio has gone down 1229.1.
Below are key valuation metrics over time for RXRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RXRX | 2023-09-22 | 34.2 | 3.6 | -6.6 | -5.2 |
| RXRX | 2023-09-21 | 34.4 | 3.7 | -6.6 | -5.2 |
| RXRX | 2023-09-20 | 35.1 | 3.7 | -6.7 | -5.4 |
| RXRX | 2023-09-19 | 36.4 | 3.9 | -7.0 | -5.6 |
| RXRX | 2023-09-18 | 37.7 | 4.0 | -7.2 | -5.9 |
| RXRX | 2023-09-15 | 37.0 | 3.9 | -7.1 | -5.7 |
RXRX Price Target
For more insight on analysts targets of RXRX, see our RXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.40 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Recursion Pharmaceuticals Inc. (RXRX) Company Bio
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.
Latest RXRX News From Around the Web
Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
Is Recursion Pharmaceuticals Stock a Buy?Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to making the company a success. The company uses machine learning and believes it can help modernize drug discovery. |
25 Biggest Stocks with Negative BetaIn this article, we will take a look at the 25 biggest stocks with negative beta. To see more such companies, go directly to 5 Biggest Stocks with Negative Beta. Stock markets were in see-saw mode before the Fed’s September decision on rate hikes. Markets gained on September 11 after positive data from China and […] |
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech MegatrendGinkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today. |
3 Stocks Cathie Wood Is Buying That Should Be on Your List, TooWarren Buffett has been a net seller of stocks in recent months, but it's a different story for Cathie Wood. If you're an aggressive investor, here are three stocks that Wood is buying that should be on your list, too. Wood's flagship Ark Innovation ETF added to its existing position in Beam Therapeutics (NASDAQ: BEAM) over the last several weeks. |
Insider Sell: CFO Michael Secora Sells 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX)On September 13, 2023, Michael Secora, the Chief Financial Officer (CFO) of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 50,000 shares of the company. |
RXRX Price Returns
| 1-mo | -16.12% |
| 3-mo | N/A |
| 6-mo | 18.60% |
| 1-year | -28.10% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -0.78% |
| 2022 | -54.99% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...